References
- 1. Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)- negative, progesterone receptor (PR)- negative, and HER2- negative invasive breast cancer, the so-called triplenegative phenotype: a population-based study from the California cancer Registry // Cancer, 2007; 1721 - 1728
- 2. Dent R, Trudeau M, Triple- negative Breast Cancer: Clinical features and Patterns of Recurrence // Clin Cancer Res, 2007; 1:4429 - 4434
- 3. Freedman GM, Anderson PR, Li T, et al. Locoregional recurrence of triple- negative breast cancer after breast- conserving surgery and radiation // Cancer, 2009; 946-951
- 4. Foulkes WD, Metcalfe K, Hanna W, et al. Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA-1 related breast carcinoma // Cancer, 2004; 64:830 - 5
- 5. Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple- negative early- stage breast cancer // J Clin Oncol, 2009; 5652-5657
- 6. Njugen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen, progesterone receptor, and HER-2, is associated with local and distant recurrence after breast- conserving therapy // J Clin Oncol, 2008; 2373- 2378
- 7. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma // Clin Cancer Res, 2004; 10:5367 - 74
- 8. Parker CC, Ampil F, Burton G, et al. Is breast conservation therapy a viable option for patients with triple- receptor negative breast cancer? // Surgery, 2010; 386-391